Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Patrick Lipps; Ana Beatriz Ayroza Galvão Ribeiro Gomes; Laila Kulsvehagen; Matthias A. Mutke; Jens Kühle; Athina Papadopoulou; Anne‐Katrin Pröbstel

doi:10.1001/jamaneurol.2023.3956

October 10, 2023JAMA NeurologyOpen Access

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to assess the effectiveness of proposed diagnostic criteria for MOGAD in differentiating it from other conditions like multiple sclerosis.
Cross-sectional study design focused on diagnostic criteria for MOGAD.
Evaluation of proposed criteria in the context of multiple sclerosis diagnosis.
Analysis of results from cell-based assays.
Diagnostic criteria may not adequately exclude multiple sclerosis and other diseases.
Cell-based assay results indicate potential overlap in diagnoses.

Abstract

This cross-sectional study examines whether proposed myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) diagnostic criteria can exclude other diseases, such as multiple sclerosis, and rely on results of cell-based assays.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipps et al. (2023) studied this question.

synapsesocial.com/papers/6a626ce70579a17fd4c960dc https://doi.org/10.1001/jamaneurol.2023.3956

View Full Paper

Ask AI

Bookmark

Share

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Key Points

Abstract

Discussion

Cite This Study

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading